Introduction
During the last War, intensive research was undertaken by the Board of Malarial Studies, U.S.A., and as a consequence a vast amount of information on both old and new antimalarial drugs has accumulated. More than 14,000 substances were tested against avian malaria, and about 100 promising compounds were tried in human malaria. Detailed chemical and pharmacological investigations including absorption, excretion, tissue distribution and toxicity studies were also undertaken. From this co-ordinated effort emerged very useful contributions :
(i) synthesis of newer 4-aminoquinolines, viz, chloroquine (from earlier German formula), and camoquin; (i'i) development of 8-aminoquinolines of lower toxicity but higher chemotherapeutic index than pamaquin, viz, pentaquine (SN-13276) , isopentaquine (SN-13274) and primaquine (SN-13272); (in) pharmacological observations providing rational use of the different antimalarials; and (iv) effective chemoprophylaxis. A comprehensive account has appeared in a monogram entitled ' A survey of Antimalarial drugs (Wiselogle, 1946) ' . Similar studies Were also undertaken by the British workers leading to the discovery of diguanides, viz, proguanil. Thus during the" last few years a powerful array of excellent drugs has been developed which has revolutionised the treatment and drug prophylaxis of malaria. The various chemotherapeutic advances have been reviewed from time to time. (Blanchard, 1847; Covell, 1947; Cooper, 1949; Field, 1949; Bull. Ross. Inst., 1949; Coatney, 1949; Coggeshall and Craig, 1949; Kikuth, 1950 ; Kikuth and Mudro Reichnow, 1949; Davey, 1951; Findlay, 1951; W.H.O. reports, 1951; Staub, 1^51; Bertagna, 1951) .
The recent discovery of the exo-erythrocytic phase of the malaria parasite Shortt and Garnham, 1948a Shortt and Garnham, 19486; Shortt et al., 1949 Shortt et al., 1951 has opened up a new field for further research, and chemotherapeutic studies have been directed to the exo-erythrocvtic stages; it is expected that an ideal antimalarial drug will be found possessing activity against these tissue forms as well as the blood forms of malaria parasites (Coatney and Cooper, 1948; Coulston and Huff, 1948 Attempts have also been made to improve the activity upon the parent drug, proguanil by preparing the different analogues of diguanides (Bami, Iyer and Guha, 1947a , 19476, 1947c , 19486, 1949 Bami, 1948 Bami, , 1950 Roy, Iyer and Guha, 1948 Guha, , 1950 Gupta, Iyer and Guha, 1948a, 19486; , 19526, 1952c . Some of these drugs were tested at the Malaria Institute of India and only a few of them exhibited antimalarial activity (Singh et al., 1949) , the most active being the bromoguanide which was found to possess appreciable activity against avian and simian strains comparable to proguanil. Further work included the synthesis of a number of diguanides of sulphides and sulphones and sulpha-guanidin,es (Jayasimha, Bhattacharya and Guha, 1951a, 19516) . Preliminary testing of these drugs showed marked activity in some of them and further pharmacological and toxicity studies are in progress.
M-5943 (Nr3 : 4-dichlorophenyl N5-isopropyl diguanide) I.C.I, was reported to be more active than proguanil against blood and preerythrocytic stages of the experimental avian infections (P. relictum and P. gallinaceum) (Crowther et al., 1950; Curd et al., 1950) . The results were however not encouraging when tested in human infections at the School of Tropical Medicine, Calcutta (Chaudhuri, Rai Chaudhuri and Dutta, 1951) , but because of the ease with which this group of compounds can be synthesized, it is not unlikely that a potent curative drug may yet be found amongst the many possible derivatives of diguanides.
The following compounds were synthesized at the Haffkine Institute, Bombay?(a) Thiazole derivatives with, p-chlorophenyl-amino group attached to the thiazole ring (6) 4-substituted amino-quinolines analogous to chloroquine (c) sulphone derivatives of quinolines (d) disubstituted amines, mono-and disubstituted thioureas and a few barbiturates (e) quinoline guanidines (Ganapathi, 1947a (Ganapathi, , 19476, 1948 (Ganapathi, , 1949 (Ganapathi, , 1950 Fernandes and Ganapathi, 1948) . A few of the 4-aminoquinolines showed antimalarial activity against the erythrocytic stages of P. gallinaceum and Guha, 1952) , but their antimalarial properties have not been well evaluated.
It would be of interest to refer here to some of the earlier works carried out in India on the subject. Row et al. (1933) and Chopra, Ganguly and Roy (1935) observed that quinine had little effect on P. knowlesi especially with heavy infections. Chopra and Das Gupta (1933 Gupta ( , 1934 and Das Gupta and Chopra (1938) failed to eradicate the infection in monkeys with mepacrine. Chopra and Das Gupta (1938) showed that P. knowlesi was susceptible to Soluseptazine but the infection was not eradicated (Chopra and Basu, 1938) . Similar results were obtained with prontosil soluble (Das Gupta and Chopra, 1938) and sulphathiazole (Dikshit and Ganapathi, 1940) . Chopra and Das Gupta (1939) and Singh and Singh (1930) found that the infection was eradicated by sulpha-pyridine. Some Indian plants, Alstonia scholaris (Chhatim) and Ccesalpina ponducella were found to have no action against animal malaria (Mukherjee, Ghosh and Siddons, 1942, 1943) . Das Gupta and Siddons (1944) found some organic arsenicals ineffective in simian malaria.
Arrangements have now been made for testing the new drugs against avian, simian and mice strains simultaneously at different institutes.
The preliminary investigations on the chemotherapeutic activity of atebrin, proguanil, resochin (chloroquine), camoquin, metachloridine, Neochin, proguanil lactate, and a few diguanides have been reported (Singh, 19496; Singh et al, 1949a, 19496 (Hitchings, 1952; Rollo, 1952 (Rollo, 1952) .
The structural group of pyrimidines essential for antimalarial activity has also offered scope for further development of potent antimalarial drugs.
A number of napthoquinones were prepared and studied by Fieser and his group (Wiselogle, 1946) and found to possess marked activities against avian plasmodia; but their effect in human malaria has been generally disappointing because of the fact that the compounds undergo metabolic degradation to inactive compounds in the human body and are toxie (Shannon, 1944) . One of them, namely lapinone (M-2350), however, has shown considerable resistance to metabolic deactivation in the body. Fawaz and Hoddard (1951) (Covell, 1943; Chaurihuri and Rai Chaudhuri, 1945; Chaudhuri, 194Sa; Chaudhuri and Dutta, 1950 Chopra, 1925) . Sinton (1930) (Napier, 1943 (Acton, 1922a , 1922b -Chopra, 1922a Sinton, 1930 (1 gm.) for 3-4 days. The close recommended for these two preparations issimilar to that of quinine, given at leas'; for 5 days. (Coveil, 1943; Napier, 1938; Chaudhuri Rai Chaudhuri, 1945 .
(b) Mepacrine.?Mepacrine is a 9 aminoacridine derivative discovered by Mauss and Mie^zsch (1933) (Hecht, 1933; Shannon et al., 1944) (Kehar, 1935a, 19356) . The effective concentration of mepacrine in the plasma necessary for alleviation of symptoms is reported to be 30 microgrammes. per litre (Ellerbrook et al., 1945) . The clinical attack is controlled within 2-3 days.
Following its introduction, the oral dosage for adults with acute attacks was empirically fixed, viz, 0.1 gm. three times a day or 0.15 gm. twice a day given at first for from seven to ten davs (Fletcher, 1933; Phelps and Jantzen. 1931 (Napier-and Das Gupta, 1932 This was confirmed by Shannon et al. (1944) and Findlay et al. (1944a, 19446 (Shannon et al., 1944; McGuin and Carmody, 1944; Hawking, 1943 (Chaudhuri, 1948; Chaudhuri and Dutta, 1950) . Khan (1951) [Jan., 1953 this can be used intravenously provided it is well diluted and given slowly.
The toxicity of mepacrine has been reviewed by Findlay (1947) . In the dosage used (1.5 gm. in four days) the toxicity of mepacrine is negligible. Occasional gastrointestinal irritation is encountered (Chopra et al, 1933) (Banerjee and Brahmachari, 1933; Army, 1934; Murray, 1934; Chopra and Chaudhuri, 1935 (1944) and Findlay (1949) (Maegraith et al, 1946; . After heavy therapeutic dosage, the plasma concentration reaches a plateau level on the third and fourth day which is maintained until the course is completed. The whole blood concentration is about three times that of plasma 75 per cent of which is protein bound (Spinks, 1947 (Fairley, 1946; Chaudhuri, 1949; Ciuca et al, 1948; Ferro Luzi, 1948; Van Riel, 1948) (Maegraith, 1948; Col-' onial Medical Research, 1949 (Chaudhuri, 1946; Afridi, 1947; Chaudhuri and Rai Chaudhuri, 1947; Pareka and Boghani, 1947a, 1947b; De and Datta, 1947a, 19476; Srivastava, 1947; Lomax, 1947; Ghose, 1947; Jafar, 1947 (Chaudhuri and Chakravarty, 1949) . Its action was not rapid, lo^al phlebitis or tissue necrosis was apt to follow, and relapses were frequent, hence there appears to be no place for this therapy (Chaudhuri et al., 1952 (Chaudhuri and Rai Chaudhuri, 1949a; Desmukh, 1950) , from Africa (Covell et al., 1949; Ferro Luzzi, 1948) and from Malaya (Edeson and Field, 1950) .
In view of the above facts it has been recommended, particularly in the treatment of falciparum cases to reinforce proguanil therapy by the administration of quinine or mepacrine or any of the 4-aminoquinolines, chloroquine or camoquin on the first day of treatment. Or conveniently, the patient may have quinine (20 to 30 gr.) or mepacrine (0.6 gm.) or chloroquine or camoquin (0.6 gm.) on the first day followed by four (or more) day course of proguanil (Covell, 1949; Chaudhuri and Dutta, 1950, and Chaudhuri et al., 1952 The drug is more toxic than proguanil and has no special advantage over quinine-pamaquin or progauanil-pamaquin in the treatment of relapsing vivax malaria (Chaudhuri, Rai Chaudhuri and Dutta, 1951) .
Another diguanide, bromoguanide was prepared at the National Institute of Science, Bangalore, and preliminary laboratory experiments were done at the Malaria Institute of India (Singh et al., 1949) . The drug was given clinical trial at the School of Tropical Medicine in doses of 100 mg. twice daily for 10 days but was found to have no special advantage over proguanil (Chaudhuri, 1951) .
(e) Chloroquine.?It was first synthesized in Germany before the World War II (Andersag et al., 1939) . It was prepared by Surrey and Hammer (1946) and was extensively studied during the War by the American investigators (Loeb et al., 1946; Most et al., 1946; Earle and Berliner, 1948; Berliner et al., 1948a; Alving et al., 1948a; Coatney et al., 1949a Coatney et al., , 1949b Like mepacrine, it is rapidly absorbed, soon becoming localized in the tissues. As it is slowly degraded and excreted and persists in the body for long periods, an initial loading dose is necessary for effective therapeutic response (Schmidt, 1946; Berliner et al., 1948a (Loeb et al., 1946) . Most et al. (1946) found that two doses of 0.3 gm. chloroquine 4 hours apart on the first day followed by single doses of 0.3 gm. on the subsequent 3 days was a completely satisfactory regimen for vivax malaria and this dose is being usecl for the routine treatment in the United States Army (United States Army, 1947a Army, , 1947b (,1951c) found chloroquine slightly superior to resochin. But similar trials of these two drugs at the School of Tropical Medicine did not show any significant difference (Chaudhuri, 1951) .
The drug is well tolerated but some untoward reactions were observed in 10 per cent cases (Chaudhuri et al, 1948 (Chaudhuri et al, , 1952 (Chaudhuri et al., 1948 (Chaudhuri et al., , 1952 (Ejercito and Duque, 1948; Simeons and Chattree, 1947; Chaudhuri and Chakravarty, 1948; Mein, 1948; Deane, 1948; Hoekenga, 1950 Hoekenga, , 1951 Chaudhuri et al, 1951; Coda, 19506; De Lucena, 1950; Villarejoi, 1951; Wallace, 1951) . Simeons and Chattree (1947) found that 10 mg. per kg. was the effective dose. Chaudhuri and Chakravarty (1948) observed that a single dose of 0,5 gm. brings about a clinical cure and appeared superior to 0.6 gm. in divided doses (0.1 gm. twice daily for 3 days). The drug was also used in doses of 0.4 gm. to 0.6 gm. on first day and 0.2 gm. on second and third days (Chaudhuri and Dutta, 1950 Hamilton, 1950 (Patel and Meahta, 1948 Jones, 1950; Monk, 1948) . On the other hand some workers found camoquin more successful than chloroquine and other antimalarials (Mein and Rosedo, 1947 (Adams and Sanderson, 1945a , 19456, 1945c , 1945d Das Gupta et al., 1945; Findlay, 1945 (Hitchings, 1952; Rollo, 1952; Goodwin, 1952; Coatney, 1952; and Discussion, 1952) . Clinical trials are now being carried out by a number of malariologists in many parts of the World. Some reports have, been encouraging (Schneider et al., 19526; Schneider, Montezin and Biheu, 1952a, 19526 Many organometallic compounds were also tried. Sinton (1927) found Stovarsol effective in vivax infection by destroying the young trophozoites when they had reached certain stages of development. A combination of quinineacetarsal was tested but the relapse rate in vivax infection was no better than in those treated with cinchona alkaloids (Sinton, Bird and Eate, 1928 The fact that aureomycin in high doses has some .activity against P. gallinaceiim and P. vivax suggested the trials of newer antibiotics in human malaria (Coatney et al. 1949a (Coatney et al. , 19496, 1950 . Later trials have shown that aureomycin has no beneficial effect in malaria therapy. Terramycin was also tried but the effect was unsatisfactory (Chaudhuri, 1951; Ruiz Sanchez et al., 1952 (Chaudhuri, 1949 Chaudhuri and Rai Chaudhuri, 19496 (Edgcomb et al., 1950 (Edgcomb et al., 1950) .
Pamaquin and other 8-aminoquinolines have relatively weak action on asexual erythrocytic stages (Covell, 1943; Berliner et al. 19486; Fairley et al, 1947) . The practical usefulness results from the fact that they influence the persistent tissue forms responsible for vivax relapses, an effect which is enhanced by the concurrent administration of quinine or chloroquine. In toxic dosage they destroy the preerythrocytic stages of P. falciparum and P. vivax (James, Nicol and Shute, 1931; Feldman et al., 1947; Fairley et al., 1947; Jones et al., 1948) . Small doses of pamaquin (e.g. 10 mg. three times daily for 3-5 days) eliminate gametocytes of P. falciparum (Covell, 1943; Cooper, 1949) . It is also probable that the other 8-aminoquinolines are also good gametocides but unfortunately they have not been investigated from this view point.
Pamaquin and other 8-aminoquinolines are localized only to a moderate degree in tissues and quickly metabolised. The plasma concentration falls very rapidly; and consequently with these drugs frequent high doses are required and not loading and maintenance doses. The plasma levels are markedly increased by the concurrent administration of mepacrine and proguanil but not by quinine (Zubrod et al., 1948; Jones et al., 1948) . However, these higher plasma levels did not enhance the antimalarial effect, but led to increased toxicity. Due to absence of correlation between the antimalarial effects observed and plasma concentration ^ of the drugs, it was suggested that the 8-aminoquinolines acted in the body through the formation of one or more active metabolic products.
Recent studies have shown that pamaquin is changed to more active metabolite. This product has been found identical to 8-diethylamino-l-methylbutylamino 5-6 quinoline quinone (Josephson et al., 1951 (Manifold, 1931; Jarvis, 1932a, 19326; Dixon, 1933; but relapse rate could not be accurately followed up and it was felt that such a prolonged treatment would not be appreciated by the people.
(?) Proguanil-pamaquin.?-During earlier trials with proguanil it was thought by some workers that a combination of proguanil and pamaquin would be useful for the prevention of relapses as both the drugs are said to act against the tissue forms. Favourable reports on this combination were published by Fairley (1946) but in a small series of cases quinine-pamaquin was found superior to prcguanil-pamaquin both in respect to relapse rate and toxicity . Monke? aL (1946) Nations, 1937; Bird, 1944; Covell, 1943 (Alving et al., 19486; Alving 1948; Loeb, et al., 1946; Staub and Gennis, 1950; Craige et al., 1948; Berliner et al., 1946) Coggeshall, 1952) . Details of these extensive clinical trials, field trials and large scale toxicity studies on returned service men from Korea have been recently reported (Alving et al., 1952; Garrison et al., 1952; Clayman et al., 1952; Hockwald et al., 1952 (Chaudhuri, 1952 (Banerjee, 1949; Desai, 1951) . Goldsmith (1946) (Chaudhuri, 1947 (Chaudhuri, , 1948 (Chaudhuri, , 1949 (Chaudhuri, , 1951 (Chaudhuri, , 1952 Chaudhuri and Poti, 1950; Chaudhuri et al., 1952) (Chaudhuri and Chakravarti, 1952 (Vincke, 1951; Archibald, 1951 Argument against proguanil prophylaxis in the field has been raised recently by Edeson and Field (1950) With regard to the chemoprophylactic trials in India the conclusion reached (Chaudhuri et al., 1952) 
